[1] R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2020, CA Cancer J Clin, 70 (2020) 7-30.
[2] W. Chen, R. Zheng, P.D. Baade, S. Zhang, H. Zeng, F. Bray, A. Jemal, X.Q. Yu, J. He, Cancer statistics in China, 2015, CA Cancer J Clin, 66 (2016) 115-132.
[3] R. Mlange, D. Matovelo, P. Rambau, B. Kidenya, Patient and disease characteristics associated with late tumour stage at presentation of cervical cancer in northwestern Tanzania, BMC Womens Health, 16 (2016) 5.
[4] S. Gupta, A. Maheshwari, P. Parab, U. Mahantshetty, R. Hawaldar, S. Sastri Chopra, R. Kerkar, R. Engineer, H. Tongaonkar, J. Ghosh, S. Gulia, N. Kumar, T.S. Shylasree, R. Gawade, Y. Kembhavi, M. Gaikar, S. Menon, M. Thakur, S. Shrivastava, R. Badwe, Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial, J Clin Oncol, 36 (2018) 1548-1555.
[5] K.S. Tewari, M.W. Sill, H.J. Long, 3rd, R.T. Penson, H. Huang, L.M. Ramondetta, L.M. Landrum, A. Oaknin, T.J. Reid, M.M. Leitao, H.E. Michael, B.J. Monk, Improved survival with bevacizumab in advanced cervical cancer, N Engl J Med, 370 (2014) 734-743.
[6] C.F. Friedman, A. Snyder Charen, Q. Zhou, M.A. Carducci, A. Buckley De Meritens, B.R. Corr, S. Fu, T.J. Hollmann, A. Iasonos, J.A. Konner, P.A. Konstantinopoulos, S.C. Modesitt, E. Sharon, C. Aghajanian, D. Zamarin, Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer, J Immunother Cancer, 8 (2020).
[7] A. Gadducci, S. Cosio, Pharmacological Treatment of Patients with Metastatic, Recurrent or Persistent Cervical Cancer Not Amenable by Surgery or Radiotherapy: State of Art and Perspectives of Clinical Research, Cancers (Basel), 12 (2020).
[8] H.W. Hirte, J.E. Strychowsky, T. Oliver, M. Fung-Kee-Fung, L. Elit, A.M. Oza, Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review, Int J Gynecol Cancer, 17 (2007) 1194-1204.
[9] L. Zhou, Y. Jiang, Q. Luo, L. Li, L. Jia, Neddylation: a novel modulator of the tumor microenvironment, Molecular cancer, 18 (2019) 77.
[10] J. Zou, H. Su, Targeting neddylation E2 for anticancer therapy, putting new wine into new bottles?, EBioMedicine, 45 (2019) 3-4.
[11] M. Wang, B.C. Medeiros, H.P. Erba, D.J. DeAngelo, F.J. Giles, R.T. Swords, Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer, Expert Opin Ther Targets, 15 (2011) 253-264.
[12] W.C. Lin, K.L. Kuo, C.S. Shi, J.T. Wu, J.T. Hsieh, H.C. Chang, S.M. Liao, C.T. Chou, C.K. Chiang, W.S. Chiu, T.Y. Chiu, Y.S. Pu, I.L. Ho, Z.H. Wang, S.C. Chang, S.H. Liu, Y.M. Jeng, K.H. Huang, MLN4924, a Novel NEDD8-activating enzyme inhibitor, exhibits antitumor activity and enhances cisplatin-induced cytotoxicity in human cervical carcinoma: in vitro and in vivo study, Am J Cancer Res, 5 (2015) 3350-3362.
[13] L. Zhou, W. Zhang, Y. Sun, L. Jia, Protein neddylation and its alterations in human cancers for targeted therapy, Cell Signal, 44 (2018) 92-102.
[14] R.I. Enchev, D.C. Scott, P.C. da Fonseca, A. Schreiber, J.K. Monda, B.A. Schulman, M. Peter, E.P. Morris, Structural basis for a reciprocal regulation between SCF and CSN, Cell Rep, 2 (2012) 616-627.
[15] H. Zhang, A. Zhong, J. Sun, M. Chen, S. Xie, H. Zheng, Y. Wang, Y. Yu, L. Guo, R. Lu, COPS5 inhibition arrests the proliferation and growth of serous ovarian cancer cells via the elevation of p27 level, Biochem Biophys Res Commun, 493 (2017) 85-93.
[16] L. Sui, Y. Dong, M. Ohno, Y. Watanabe, K. Sugimoto, Y. Tai, M. Tokuda, Jab1 expression is associated with inverse expression of p27(kip1) and poor prognosis in epithelial ovarian tumors, Clin Cancer Res, 7 (2001) 4130-4135.
[17] S. Jumpertz, T. Hennes, Y. Asare, A.K. Schutz, J. Bernhagen, CSN5/JAB1 suppresses the WNT inhibitor DKK1 in colorectal cancer cells, Cell Signal, 34 (2017) 38-46.
[18] A. Fukumoto, N. Ikeda, M. Sho, K. Tomoda, H. Kanehiro, M. Hisanaga, Y. Tsurui, M. Tsutsumi, J.Y. Kato, Y. Nakajima, Prognostic significance of localized p27Kip1 and potential role of Jab1/CSN5 in pancreatic cancer, Oncology reports, 11 (2004) 277-284.
[19] M.A. Kouvaraki, G.Z. Rassidakis, L. Tian, R. Kumar, C. Kittas, F.X. Claret, Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27 (Kip1), Cancer Res, 63 (2003) 2977-2981.
[20] A. Zemla, Y. Thomas, S. Kedziora, A. Knebel, N.T. Wood, G. Rabut, T. Kurz, CSN- and CAND1-dependent remodelling of the budding yeast SCF complex, Nat Commun, 4 (2013) 1641.
[21] T.J. Shackleford, F.X. Claret, JAB1/CSN5: a new player in cell cycle control and cancer, Cell Div, 5 (2010) 26.
[22] Y. Pan, S. Wang, B. Su, F. Zhou, R. Zhang, T. Xu, R. Zhang, V. Leventaki, E. Drakos, W. Liu, F.X. Claret, Stat3 contributes to cancer progression by regulating Jab1/Csn5 expression, Oncogene, 36 (2017) 1069-1079.
[23] A. Yoshida, N. Yoneda-Kato, M. Panattoni, R. Pardi, J.Y. Kato, CSN5/Jab1 controls multiple events in the mammalian cell cycle, FEBS letters, 584 (2010) 4545-4552.
[24] A.K. Schutz, T. Hennes, S. Jumpertz, S. Fuchs, J. Bernhagen, Role of CSN5/JAB1 in Wnt/beta-catenin activation in colorectal cancer cells, FEBS letters, 586 (2012) 1645-1651.
[25] G.Z. Rassidakis, F.X. Claret, R. Lai, Q. Zhang, A.H. Sarris, T.J. McDonnell, L.J. Medeiros, Expression of p27(Kip1) and c-Jun activation binding protein 1 are inversely correlated in systemic anaplastic large cell lymphoma, Clinical cancer research : an official journal of the American Association for Cancer Research, 9 (2003) 1121-1128.
[26] K. Tomoda, Y. Kubota, Y. Arata, S. Mori, M. Maeda, T. Tanaka, M. Yoshida, N. Yoneda-Kato, J.Y. Kato, The cytoplasmic shuttling and subsequent degradation of p27Kip1 mediated by Jab1/CSN5 and the COP9 signalosome complex, The Journal of biological chemistry, 277 (2002) 2302-2310.
[27] H.Z. Cao, X.F. Liu, W.T. Yang, Q. Chen, P.S. Zheng, LGR5 promotes cancer stem cell traits and chemoresistance in cervical cancer, Cell death & disease, 8 (2017) e3039.
[28] C. Artaza-Irigaray, A. Molina-Pineda, A. Aguilar-Lemarroy, P. Ortiz-Lazareno, L.P. Limon-Toledo, A.L. Pereira-Suarez, W. Rojo-Contreras, L.F. Jave-Suarez, E6/E7 and E6(*) From HPV16 and HPV18 Upregulate IL-6 Expression Independently of p53 in Keratinocytes, Front Immunol, 10 (2019) 1676.
[29] J. Zhao, Cancer stem cells and chemoresistance: The smartest survives the raid, Pharmacol Ther, 160 (2016) 145-158.
[30] S.T. Nawrocki, P. Griffin, K.R. Kelly, J.S. Carew, MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy, Expert Opin Investig Drugs, 21 (2012) 1563-1573.